nach oben

Erschienen in:

28.10.2023 | Original Article

Genetic polymorphisms as predictive biomarkers of adverse events during preoperative chemotherapy in esophageal cancer

verfasst von: Yao Liang, Osamu Maeda, Kazushi Miyata, Mitsuro Kanda, Shizuki Sugita, Dai Shimizu, Kazuki Nishida, Yasuhiro Kodera, Yuichi Ando

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aimed to explore associations between genetic polymorphisms and adverse effects due to preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil (DCF) for esophageal cancer.

Methods

Preoperative DCF (docetaxel, 70 mg/m²/day, day 1; cisplatin, 70 mg/m²/day, day 1; fluorouracil, 750 mg/m²/day, days 1–5) was repeated every 3 weeks for up to three cycles. Genotyping of nine candidate genetic polymorphisms was conducted using blood samples from the enrolled patients.

Results

According to a multivariable analysis evaluating 50 patients, grade 3 or worse neutropenia was more likely to occur in those with the ABCC2-24C/T or T/T genotype (rs717620) (OR, 5.30, P = 0.013). Additionally, patients with the TYMS 3′-UTR 0 bp/0 bp genotype (rs151264360) showed a trend toward grade 3 or worse hyponatremia (OR, 0.16, P = 0.005). Grade 2 or worse thrombocytopenia was more likely to occur in patients with the TNF-α-1031C/T or T/T genotype (rs1799964) (OR, 6.30, P = 0.016) and IL-6-634C/C genotype (rs1800796) (OR, 0.18, P = 0.034), and grade 2 or worse anemia was more likely to occur in patients with the MCP-1-2518G/G genotype (rs1024611) (OR, 0.19, P = 0.027).

Conclusions

ABCC2-24C > T (rs717620), TYMS 3′-UTR 6-bp indel (rs151264360), TNF-α-1031T > C (rs1799964) as well as IL-6-634G > C (rs1800796), and MCP-1-2518A > G (rs1024611) polymorphisms might serve as independent and predictive biomarkers for neutropenia, hyponatremia, thrombocytopenia, and anemia, respectively, during preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for patients with esophageal cancer.

Nur mit Berechtigung zugänglich

Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y, Ueda J, Wei W, Inoue M, Tanaka H (2013) Epidemiology of esophageal cancer in Japan and China. J Epidemiol 23(4):233–242CrossRefPubMed

Medical Research Council Oesophageal Cancer Working Party (2002) Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet (London, England) 359(9319):1727–1733CrossRef

Matsuda S, Kitagawa Y, Takemura R, Okui J, Okamura A, Kawakubo H, Muto M, Kakeji Y, Takeuchi H, Watanabe M, Doki Y (2022) Real-world evaluation of the efficacy of neoadjuvant DCF over CF in esophageal squamous cell carcinoma: propensity score matched analysis from 85 authorized institutes for esophageal cancer in Japan. Ann Surg. https://doi.org/10.1097/SLA.0000000000005533CrossRefPubMed

Hara H, Tahara M, Daiko H, Kato K, Igaki H, Kadowaki S, Tanaka Y, Hamamoto Y, Matsushita H, Nagase M, Hosoya Y (2013) Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci 104(11):1455–1460. https://doi.org/10.1111/cas.12274CrossRefPubMedPubMedCentral

Bins S, Huitema ADR, Laven P, Bouazzaoui SE, Yu H, van Erp N, van Herpen C, Hamberg P, Gelderblom H, Steeghs N, Sleijfer S, van Schaik RHN, Mathijssen RHJ, Koolen SLW (2019) Impact of CYP3A4*22 on pazopanib pharmacokinetics in cancer patients. Clin Pharmacokinet 58(5):651–658. https://doi.org/10.1007/s40262-018-0719-5CrossRefPubMed

Li J, Wang X, Ning C, Wang Z, Wang Y, Zheng M, Zhang S, Lu Y, Zhang Y, Li N, Chen X, Zhao D (2020) Influences of ABC transporter and CYP3A4/5 genetic polymorphisms on the pharmacokinetics of lenvatinib in Chinese healthy subjects. Eur J Clin Pharmacol 76(8):1125–1133. https://doi.org/10.1007/s00228-020-02879-zCrossRefPubMed

Evans WE, McLeod HL (2003) Pharmacogenomics–drug disposition, drug targets, and side effects. N Engl J Med 348(6):538–549CrossRefPubMed

Sone K, Oguri T, Uemura T, Takeuchi A, Fukuda S, Takakuwa O, Maeno K, Fukumitsu K, Kanemitsu Y, Ohkubo H, Takemura M, Ito Y, Niimi A (2019) Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort. BMC Cancer 19(1):246. https://doi.org/10.1186/s12885-019-5438-2CrossRefPubMedPubMedCentral

Lam SW, Guchelaar HJ, Boven E (2016) The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer Treat Rev. https://doi.org/10.1016/j.ctrv.2016.08.001CrossRefPubMed

10.

Tsukaguchi H, Tokui T, Mackenzie B, Berger UV, Chen XZ, Wang Y, Brubaker RF, Hediger MA (1999) A family of mammalian Na+-dependent L-ascorbic acid transporters. Nature 399(6731):70–75ADSCrossRefPubMed

11.

Minegaki T, Takara K, Hamaguchi R, Tsujimoto M, Nishiguchi K (2013) Factors affecting the sensitivity of human-derived esophageal carcinoma cell lines to 5-fluorouracil and cisplatin. Oncol Lett 5(2):427–434CrossRefPubMed

12.

Minegaki T, Kuwahara A, Yamamori M, Nakamura T, Okuno T, Miki I, Omatsu H, Tamura T, Hirai M, Azuma T, Sakaeda T, Nishiguchi K (2014) Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci 11(4):321–326. https://doi.org/10.7150/ijms.7654CrossRefPubMedPubMedCentral

13.

Yousefian-Jazi A, Jung J, Choi JK, Choi J (2020) Functional annotation of noncoding causal variants in autoimmune diseases. Genomics 112(2):1208–1213. https://doi.org/10.1016/j.ygeno.2019.07.006CrossRefPubMed

14.

Kitamura A, Hasegawa G, Obayashi H, Kamiuchi K, Ishii M, Yano M, Tanaka T, Yamaguchi M, Shigeta H, Ogata M, Nakamura N, Yoshikawa T (2002) Interleukin-6 polymorphism (-634C/G) in the promotor region and the progression of diabetic nephropathy in type 2 diabetes. Diabet Med J Br Diabet Assoc 19(12):1000–1005CrossRef

15.

Rovin BH, Lu L, Saxena R (1999) A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 259(2):344–348CrossRefPubMed

16.

Sakamoto K, Oka M, Yoshino S, Hazama S, Abe T, Okayama N, Hinoda Y (2006) Relation between cytokine promoter gene polymorphism and toxicity of 5-fluorouracil plus cisplatin chemotherapy. Oncol Rep 16(2):381–387PubMed

17.

Fujita K, Motoyama S, Sato Y, Yoshino K, Sasaki T, Liu J, Niioka T, Anbai A, Minamiya Y, Miura M (2016) IL-6 and MCP-1 genetic polymorphisms are predictive of decreased platelet counts caused by chemoradiotherapy in esophageal cancer. Esophagus 13(3):264–269. https://doi.org/10.1007/s10388-016-0522-zCrossRef

18.

Brierley JD, Gospodarowicz MK, Wittekind C (2017) TNM classification of malignant tumours. Wiley

19.

Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31–41CrossRefPubMed

20.

Nomura H, Tsuji D, Demachi K, Mochizuki N, Matsuzawa H, Yano T, Daiko H, Fujii S, Kojima T, Itoh K, Kawasaki T (2020) ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy. Cancer Chemother Pharmacol 86(2):315–324. https://doi.org/10.1007/s00280-020-04118-9CrossRefPubMed

21.

Fujita K, Motoyama S, Sato Y, Wakita A, Nagaki Y, Minamiya Y, Miura M (2022) Association between ABCC2 polymorphism and hematological toxicity in patients with esophageal cancer receiving platinum plus 5-fluorouracil therapy. Esophagus Off J Japan Esophageal Soc 19(1):146–152. https://doi.org/10.1007/s10388-021-00865-7CrossRef

22.

Arakawa Y, Shirai Y, Hayashi K, Tanaka Y, Matsumoto A, Nishikawa K, Yano S (2018) Effects of gene polymorphisms on the risk of severe hyponatremia during DCF chemotherapy for patients with esophageal squamous cell carcinoma. Oncol Lett 16(4):5455–5462. https://doi.org/10.3892/ol.2018.9236CrossRefPubMedPubMedCentral

23.

Firth D (1993) Bias reduction of maximum likelihood estimates. Biometrika 80(1):27–38. https://doi.org/10.2307/2336755MathSciNetCrossRef

24.

Laechelt S, Turrini E, Ruehmkorf A, Siegmund W, Cascorbi I, Haenisch S (2011) Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics J 11(1):25–34. https://doi.org/10.1038/tpj.2010.20CrossRefPubMed

25.

Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S, Lenz H-J, Ladner RD (2004) A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics Genom 14(5):319–327CrossRef

26.

Lecomte T, Ferraz J-M, Zinzindohoué F, Loriot M-A, Tregouet D-A, Landi B, Berger A, Cugnenc P-H, Jian R, Beaune P, Laurent-Puig P (2004) Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 10(17):5880–5888. https://doi.org/10.1158/1078-0432.CCR-04-0169CrossRefPubMed

27.

Chu T, Hu S, Qi J, Li X, Zhang X, Tang Y, Yang M, Xu Y, Ruan C-G, Han Y, Wu D-P (2022) Bifunctional effect of the inflammatory cytokine tumor necrosis factor α on megakaryopoiesis and platelet production. J Thromb Haemost: JTH 20(12):2998–3010. https://doi.org/10.1111/jth.15891CrossRefPubMed

28.

Nourian M, Chaleshi V, Pishkar L, Azimzadeh P, Baradaran Ghavami S, Balaii H, Alinaghi S, Shahrokh S, Asadzadeh Aghdaei H, Zali MR (2017) Evaluation of tumor necrosis factor (TNF)-α mRNA expression level and the rs1799964 polymorphism of the TNF-α gene in peripheral mononuclear cells of patients with inflammatory bowel diseases. Biomed Rep 6(6):698–702. https://doi.org/10.3892/br.2017.908CrossRefPubMedPubMedCentral

29.

Kaushansky K (1998) Thrombopoietin. N Engl J Med 339(11):746–754CrossRefPubMed

30.

Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, Theurl I, Widder W, Molnar C, Ludwiczek O, Atkins MB, Mier JW, Tilg H (2001) Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 98(9):2720–2725CrossRefPubMed

31.

Mahoney SE, Davis JM, Murphy EA, McClellan JL, Gordon B, Pena MM (2013) Effects of 5-fluorouracil chemotherapy on fatigue: role of MCP-1. Brain Behav Immun 27(1):155–161. https://doi.org/10.1016/j.bbi.2012.10.012CrossRefPubMed

32.

Sakamoto K, Takeda S, Kanekiyo S, Nishiyama M, Kitahara M, Ueno T, Yamamoto S, Yoshino S, Hazama S, Okayama N, Nagano H (2017) Association of tumor necrosis factor-α polymorphism with chemotherapy-induced oral mucositis in patients with esophageal cancer. Mol Clin Oncol 6(1):125–129. https://doi.org/10.3892/mco.2016.1081CrossRefPubMed

33.

White C, Scott RJ, Paul C, Ziolkowski A, Mossman D, Fox SB, Michael M, Ackland S (2022) Dihydropyrimidine dehydrogenase deficiency and implementation of upfront DPYD genotyping. Clin Pharmacol Ther 112(4):791–802. https://doi.org/10.1002/cpt.2667CrossRefPubMed

34.

Engels FK, Ten Tije AJ, Baker SD, Lee CKK, Loos WJ, Vulto AG, Verweij J, Sparreboom A (2004) Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 75(5):448–454CrossRefPubMed

Titel: Genetic polymorphisms as predictive biomarkers of adverse events during preoperative chemotherapy in esophageal cancer
verfasst von: Yao Liang
Osamu Maeda
Kazushi Miyata
Mitsuro Kanda
Shizuki Sugita
Dai Shimizu
Kazuki Nishida
Yasuhiro Kodera
Yuichi Ando
Publikationsdatum: 28.10.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 2/2024
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-023-04607-7

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Genetic polymorphisms as predictive biomarkers of adverse events during preoperative chemotherapy in esophageal cancer